Resmed Inc.
RMD
Get informed when a big investor buys or sells
+ FollowEarnings Call Q3 2026
April 30, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
162.2% upsideUndervalued by 162.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.64 Billion |
|---|---|
| Enterprise Value | $27.17 Billion |
| Dividend Yield | $2.40 (1.26%) |
| Earnings per Share | $9.55 |
| Beta | 0.85 |
| Outstanding Shares | 146,472,000 |
Return
| Return on Equity | 23.41% |
|---|---|
| Return on Assets | 17.30% |
| Return on Invested Capital | 25.63% |
Valuation & Multiples
| P/E Ratio | 18.37 |
|---|---|
| PEG | 199.03 |
| Price to Sales | 5.04 |
| Price to Book Ratio | 4.24 |
| Enterprise Value to Revenue | 4.91 |
| Enterprise Value to EBIT | 14.26 |
| Enterprise Value to Net Income | 17 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.18 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 3.6636▲ 27.70% |
|---|---|
| Total Calls | 230,100▼ 25.56% |
| Total Puts | 843,000▼ 19.47% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 66.28%▲ 0.06% |
|---|---|
| Total Invested | $21.69B▼ 7.19% |
| Investors Holding | 957▼ 20.00% |
ESG Score
No data
About Resmed Inc.
CEO: Michael Farrell Relevant Senate Committees
This committee controls taxation, trade, and entitlement spending (Medicare, Medicaid). Its decisions directly impact Resmed's corporate tax burden, supply chain costs, and the reimbursement rates and coverage for its medical devices.
This committee directly allocates federal spending. Its subcommittees determine precise funding for healthcare programs (e.g., HHS, VA), directly impacting reimbursement for Resmed's products and government purchasing.
This committee directly regulates the FDA, which is the primary body overseeing medical device approval, manufacturing standards, and post-market surveillance—all critical to Resmed's operations.
This committee's oversight of intellectual property (patents for medical devices) and antitrust laws directly impacts Resmed's competitive landscape, innovation protection, and potential M&A activities.
Resmed's respiratory and sleep apnea devices are highly relevant to veterans' healthcare. Committee funding decisions for the Department of Veterans Affairs directly impact procurement and services for medical device manufacturers selling to the VA.